Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND (MIND)
Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Milan, Italy
- Fondazione IRCCS Istituto Neurologico Carlo Besta
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Inclusion Criteria (Retrospective & Prospective):
- Patient aged 18 years or older.
- First diagnosis of uni-focal meningioma of the convexity.
- Macroscopical total resection (Simpson 1-3).
(Retrospective only):
- Surgery performed between 2007 and 2016;
- availability of FFPE sample and medical records.
Exclusion Criteria:
- Genetic syndromes.
- Diffuse Meningeal Meningiomatosis.
- Patients who underwent experimental treatment in neo-adjuvant setting.
(Prospective only):
- Previous surgical/medical treatment for another meningioma;
- positive oncological history (e.g., breast cancer).
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Retrospective Cohort
150 patients operated for non-recurrent meningioma between 2008 and 2016.
|
|
Prospective Cohort
60 patients diagnosed with meningioma recruited prospectively.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Definition of a novel epigenetic signature based on MS-profiling
Time Frame: Months 1-12
|
Identification of histone post-translational modifications (PTMs) patterns in FFPE tissue samples capable of classifying tumor recurrence.
|
Months 1-12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Validation of epigenetic signature in prospective tissues
Time Frame: Months 13-18
|
Validation of the histone PTMs signature using Mass Spectrometry on FFPE samples from the prospective cohort.
|
Months 13-18
|
|
Validation of epigenetic biomarkers in circulating nucleosomes
Time Frame: Months 13-20
|
Profiling histone PTMs in circulating nucleosomes from patient sera matching the tissues profiled.
|
Months 13-20
|
|
DNA methylation profiling in plasma-EVs
Time Frame: Months 10-20
|
Assessment of genome-wide DNA methylation profile from DNA extracted from plasma-derived Extracellular Vesicles.
|
Months 10-20
|
|
Development of a Machine Learning prognostic classifier
Time Frame: Months 18-24
|
Integration of epi-proteomics data, DNA-methylation profiles, and clinico-pathological information to predict recurrence.
|
Months 18-24
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MIND
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.